MaxCyte (NASDAQ:MXCT – Get Rating) is one of 39 publicly-traded companies in the “Commercial physical research” industry, but how does it compare to its competitors? We will compare MaxCyte to related businesses based on the strength of its risk, dividends, valuation, profitability, earnings, analyst recommendations and institutional ownership. Profitability This table compares MaxCyte and its […]
Analysts expect MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) to post sales of $9.00 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for MaxCyte’s earnings, with estimates ranging from $8.90 million to $9.10 million. MaxCyte reported sales of $7.11 million in the same quarter last year, which would suggest […]
MaxCyte (NASDAQ:MXCT – Get Rating) is one of 39 public companies in the “Commercial physical research” industry, but how does it compare to its peers? We will compare MaxCyte to similar companies based on the strength of its earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and dividends. Analyst Recommendations This is a summary of […]